{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T14:12:48Z","timestamp":1783174368176,"version":"3.54.6"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2019M652543"],"award-info":[{"award-number":["2019M652543"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.bcp.2019.08.012","type":"journal-article","created":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T23:24:47Z","timestamp":1566861887000},"page":"113610","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Repurposing of the anti-helminthic drug niclosamide to treat melanoma and pulmonary metastasis via the STAT3 signaling pathway"],"prefix":"10.1016","volume":"169","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5977-9579","authenticated-orcid":false,"given":"Yongxia","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqiong","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shasha","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cailin","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingping","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanglai","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinghong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2019.08.012_b0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bcp.2019.08.012_b0010","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3322\/caac.21338","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J. Clin."},{"issue":"7527","key":"10.1016\/j.bcp.2019.08.012_b0015","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1038\/515S110a","volume":"515","year":"2014","journal-title":"Nature"},{"issue":"7527","key":"10.1016\/j.bcp.2019.08.012_b0020","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1038\/515S117a","volume":"515","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2019.08.012_b0025","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","article-title":"Melanoma","volume":"392","author":"Schadendorf","year":"2018","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.bcp.2019.08.012_b0030","first-page":"6","article-title":"Multidisciplinary Approach to Patient with Malignant Melanoma","volume":"13","author":"Scarpati","year":"2013","journal-title":"Anti-Cancer Agents in Medic. Chem."},{"key":"10.1016\/j.bcp.2019.08.012_b0035","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.bcp.2013.11.008","article-title":"Quercetin exerts anti-melanoma activities and inhibits STAT3 signaling","volume":"87","author":"Cao","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2019.08.012_b0040","first-page":"202","article-title":"Melanoma: Neo\/adjuvant BRAF\/MEKi improves outcomes","volume":"15","author":"Sidaway","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bcp.2019.08.012_b0045","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.3390\/ijms19061787","article-title":"STAT3 Interactors as Potential Therapeutic Targets for Cancer Treatment","volume":"19","author":"Laudisi","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2019.08.012_b0050","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1242\/jcs.00963","article-title":"The JAK\/STAT signaling pathway","volume":"117","author":"Rawlings","year":"2004","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.bcp.2019.08.012_b0055","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1126\/science.8140422","article-title":"Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6","volume":"264","author":"Zhong","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.bcp.2019.08.012_b0060","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1038\/sj.onc.1203476","article-title":"The role of STATs in transcriptional control and their impact on cellular function","volume":"19","author":"Bromberg","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2019.08.012_b0065","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nrc3818","article-title":"Revisiting STAT3 signalling in cancer: new and unexpected biological functions","volume":"14","author":"Yu","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2019.08.012_b0070","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/107327480801500302","article-title":"Activated stat-3 in melanoma","volume":"15","author":"Messina","year":"2008","journal-title":"Cancer Control"},{"key":"10.1016\/j.bcp.2019.08.012_b0075","doi-asserted-by":"crossref","first-page":"20253","DOI":"10.1038\/srep20253","article-title":"Nifuroxazide exerts potent anti-tumor and anti-metastasis activity in melanoma","volume":"6","author":"Zhu","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2019.08.012_b0080","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3332\/ecancer.2014.485","article-title":"The Repurposing Drugs in Oncology (ReDO) Project","volume":"8","author":"Pantziarka","year":"2014","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.bcp.2019.08.012_b0085","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2019.08.012_b0090","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2019.08.012_b0095","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrd4609","article-title":"An analysis of the attrition of drug candidates from four major pharmaceutical companies","volume":"14","author":"Waring","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2019.08.012_b0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrd.2018.92","article-title":"Overcoming the legal and regulatory barriers to drug repurposing","volume":"18","author":"Breckenridge","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2019.08.012_b0105","doi-asserted-by":"crossref","first-page":"550","DOI":"10.7326\/0003-4819-102-4-550","article-title":"Niclosamide Therapy for Tapeworm Infections","volume":"102","author":"Pearson","year":"1985","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bcp.2019.08.012_b0110","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/sj.clpt.6100106","article-title":"World Health Organization program for the selection and use of essential medicines","volume":"81","author":"Reidenberg","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2019.08.012_b0115","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1021\/ml100146z","article-title":"Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway","volume":"1","author":"Ren","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2019.08.012_b0120","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1073\/pnas.0409894102","article-title":"A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells","volume":"102","author":"Song","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bcp.2019.08.012_b0125","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10555-006-7886-9","article-title":"Matrix metalloproteinases and tumor metastasis","volume":"25","author":"Deryugina","year":"2006","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.bcp.2019.08.012_b0130","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/onc.2014.143","article-title":"Activation of mTOR pathway in myeloid-derived suppressor cells stimulates cancer cell proliferation and metastasis in lal(-\/-) mice","volume":"34","author":"Zhao","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2019.08.012_b0135","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.452","article-title":"Inhibition of Stat3 signaling pathway by nifuroxazide improves antitumor immunity and impairs colorectal carcinoma metastasis","volume":"8","author":"Ye","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2019.08.012_b0140","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1158\/1078-0432.CCR-15-2256","article-title":"Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma","volume":"22","author":"Satoh","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2019.08.012_b0145","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3892\/ijmm.2016.2689","article-title":"Niclosamide inhibits colon cancer progression through downregulation of the Notch pathway and upregulation of the tumor suppressor miR-200 family","volume":"38","author":"Suliman","year":"2016","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.bcp.2019.08.012_b0150","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nrc2663","article-title":"Apoptosis and cancer: the genesis of a research field","volume":"9","author":"Cotter","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2019.08.012_b0155","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/978-1-4419-6706-0_3","article-title":"BH3-only proteins and their effects on cancer","volume":"687","author":"Vo","year":"2010","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.bcp.2019.08.012_b0160","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1158\/1078-0432.CCR-15-0364","article-title":"BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis","volume":"21","author":"Gibson","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2019.08.012_b0165","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.semcancer.2017.04.005","article-title":"Mitochondrial ROS control of cancer","volume":"47","author":"Idelchik","year":"2017","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bcp.2019.08.012_b0170","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2019.08.012_b0175","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nrc1075","article-title":"Tumour-cell invasion and migration: diversity and escape mechanisms","volume":"3","author":"Friedl","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2019.08.012_b0180","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00262-017-1988-9","article-title":"CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma","volume":"66","author":"Umansky","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bcp.2019.08.012_b0185","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1172\/JCI35213","article-title":"Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice","volume":"118","author":"Kujawski","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2019.08.012_b0190","first-page":"55","article-title":"Signaling pathways involved in MDSC regulation","volume":"2014","author":"Trikha","year":"1846","journal-title":"Biochim. Biophys. Acta, Mol. Cell. Biol. Lipids"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219303004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219303004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T12:51:21Z","timestamp":1695127881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295219303004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":38,"alternative-id":["S0006295219303004"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2019.08.012","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing of the anti-helminthic drug niclosamide to treat melanoma and pulmonary metastasis via the STAT3 signaling pathway","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2019.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113610"}}